# Danaher Q3 2026 Earnings Beat

> Danaher reports 8.5% revenue growth and 5.5% core growth excluding respiratory revenue in Q3 2026.
- Title: Danaher Q3 2026 Earnings Beat · The Motley Fool | Shortify
- Summary: Danaher reports 8.5% revenue growth and 5.5% core growth excluding respiratory revenue in Q3 2026. Danaher's Q3 2026 earnings exceeded expectations with $6.6…
- Keywords: danaher, q3 2026, earnings call, revenue growth, core growth, respiratory revenue, adjusted diluted eps, free cash flow, biotechnology, life sciences, diagnostics, masimo
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/10/21/danaher-dhr-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-10-21T16:57:54+00:00
- Read time: 1 min
- Topics: danaher, q3 2026, earnings call, revenue growth, core growth, respiratory revenue, adjusted diluted eps, free cash flow, biotechnology, life sciences, diagnostics, masimo
## Q3 2026 Results
Danaher reported third quarter revenue of $6.6 billion, representing 8.5% growth compared to Q3 2025.
## Core Revenue Growth
Core revenue growth excluding respiratory revenue reached 5.5%, accelerating 100 basis points from Q2 2026.
## Respiratory Revenue
Respiratory revenue totaled $350 million, down year over year due to lower global infection rates.
## Biotechnology Performance
Biotechnology core revenue grew 5% with bioprocessing performance toward the upper end of mid-single digits.
## Life Sciences Growth
Life Sciences core revenue grew 4.5% led by SCIEX's pharma demand and ZenoTOF 8600 momentum.
## Diagnostics Performance
Diagnostics core revenue excluding respiratory grew 7% with mid-single-digit clinical diagnostics growth.
## China Growth
China core revenue grew high single digits across all three operating segments.
## Masimo Integration
Masimo, acquired as a Danaher business, delivered high single-digit revenue growth in Q3 2026.
## Q4 Guidance
Q4 2026 core growth guidance excludes respiratory revenue at 4% to 5% with 150 basis point headwind.
## 2027 Growth Target
2027 core revenue growth starting point excludes respiratory revenue at 4% to 5%.
## Acquisitions
Leica Biosystems acquired StatLab in early Oct. 2026 to strengthen oncology pathology workflow.
## AI Partnership
Danaher announced NVIDIA partnership to advance AI-powered autonomous lab workflows.
## Free Cash Flow
Free cash flow reached $1.6 billion for Q3 2026 and $4 billion for first nine months of 2026.
## Operating Margin
Adjusted operating profit margin reached 29.0%, improving 110 basis points year over year.
## CEO Perspective
CEO Julie Sawyer Montgomery stated, 'unambiguous share gain is our true report card.'

> unambiguous share gain is our true report card
## Strategic Priorities
Danaher prioritizes commercial excellence, innovation, talent, and disciplined capital allocation.
## Key takeaway

Danaher's Q3 2026 earnings exceeded expectations with $6.6 billion revenue, 5.5% core growth excluding respiratory revenue, and $2.11 adjusted diluted EPS.